The Asia Pacific Advantage: A Strategic Hub for Global Clinical Development
For decades, the global biopharmaceutical industry regarded the Asia Pacific (APAC) region primarily through the lens of cost efficiency or as a secondary recruitment destination for late-stage trials. However, a significant structural shift is underway. Today, the region has transitioned from a supporting role in clinical development to a major driver of scientific advancement, offering scale and innovation that are now integral to global drug development strategies.
For sponsors seeking to accelerate clinical development, access differentiated innovation and generate evidence for global regulatory pathways, APAC is no longer a region to be considered later in development. It is increasingly becoming a strategic component of how global trials are planned from the outset.
A Proven Standard of Excellence
The conversation regarding clinical data quality in APAC has evolved from hesitancy to growing confidence. Large multinational pharmaceutical companies, including global leaders such as GSK and Pfizer, are now deeply comfortable in the region, with established R&D functions that prioritize growth and capacity over basic validation. This confidence reflects a broader strategic commitment to the region, as APAC continues to play an increasingly important role in global clinical development and innovation.
This confidence is underpinned by a measurable track record of performance. While markets such as Japan, Korea and Taiwan have long maintained established global standards, mainland China has recently reached a clear tipping point. Data from mainland China sites is now regularly utilized in global regulatory submissions, including those to the US FDA, with audits increasingly demonstrating alignment with global regulatory expectations.
The region offers a rare combination: incomparable scale matched by a quality standard that meets the stringent requirements of global regulators.
A Powerhouse for Scientific Versatility
The source of global biopharmaceutical innovation is shifting eastward, with the region emerging as a diversified powerhouse for multimodality innovation. Mainland China, in particular, has become a leading hub for oncology and advanced therapeutics, with over half of its innovative output currently focused on oncology research.
The market is also setting the global agenda in cell and gene therapy (CGT). Supported by sophisticated infrastructure and the ability to conduct agile investigator–sponsored studies, mainland China offers significant development speed in the CGT space. This has led to a notable trend in which global biotechnology companies are now proactively seeking to conduct early phase cell therapy studies in the market to leverage this established expertise.
Biosimilars are another clear area of regional strength. Asia is home to some of the world’s most established biosimilar developers, including Celltrion and Samsung Biologics in Korea, as well as leading players in mainland China, such as Henlius, Qilu and Bio-Thera. As more high-value biologics lose exclusivity, the ability to develop and manufacture biosimilars at scale and competitive cost is becoming increasingly important for global healthcare systems. The region is therefore well positioned to play a central role in expanding access to these therapies worldwide.
The Strategic Bridge: From Biotech Innovation to Global Approval
While large pharma is deeply comfortable in APAC, the biotech segment represents the most dynamic area of growth. For international biotechs, the region is no longer just about cost. It is about accessing differentiated innovation and first-in-class assets required to compete globally.
The most successful partnerships in the region prioritize an outcome-centric development strategy from the earliest stages. While the ability to generate early clinical data quickly is a massive advantage for proof of concept, it has to be integrated into a broader global bridging strategy. By proactively accounting for factors such as dosing and ethnicity-based differences in disease presentation, sponsors can ensure that the high-quality data generated in Asia serves as a robust foundation for global regulatory submissions, including FDA and European Medicines Agency pathways.
This strategic foresight allows biotechs to leverage the region’s advantages in speed and innovation while maintaining continuity in global development. In this context, APAC is not simply a place to run studies faster. It is a region that can help shape smarter, more globally relevant development strategies.
Need a global development strategy that starts with the right geography? Explore Global Clinical Development Solutions.
A Dynamic and Multi-Hub Ecosystem
The strategic toolkit for an international biotech in APAC is remarkably diverse, with each market offering distinct advantages:
- Mainland China: Functioning as a comprehensive innovation hub, it offers incomparable scale and a rapidly maturing ecosystem for oncology and advanced therapeutics. With a unique infrastructure that enables agile, multicenter studies in areas such as CGT, it has become a key source of global in-licensing deals and early-stage proof-of-concept data. The ecosystem continues to expand in both depth and global integration.
- Japan: As one of the world’s most established pharmaceutical markets, Japan remains a cornerstone of high-quality R&D. While its biotech ecosystem is more specialized than mainland China’s, it has a long-standing heritage of internal discovery and disciplined clinical development. The market offers a stable, predictable and highly structured environment for global clinical programs.
- Korea: Recognized for its best-in-class innovative assets and strong manufacturing capabilities, Korea combines scientific quality with operational efficiency. It is increasingly seen as a competitive source of high-value clinical and development opportunities, particularly in advanced biologics and partnership-driven development models.
- Taiwan: Serving as a high-quality pillar within the APAC clinical development ecosystem, Taiwan is known for its strong investigator network and consistent delivery of robust clinical data. It has a proven track record across multiple therapeutic areas, supported by a highly reliable research environment. Its focus on execution quality makes it a dependable trial location for consistent data generation.
- Australia: Sustaining around 20% year-on-year growth,Australia is a premier destination for early phase clinical work. Its streamlined regulatory pathways and government-backed research incentives make it a highly attractive location for first-in-human studies. The country continues to attract increasing global sponsor activity.
- India: Positioned as the operational engine of the industry, India combines deep technological capabilities with large-scale patient access. As AI adoption accelerates, its role in data management and clinical analytics is expanding. It is becoming increasingly important for operational scalability in global trials.
- Singapore: Serving as a regional headquarters and leadership hub, Singapore provides regulatory stability and strong governance frameworks. Its diverse talent pool and global connectivity make it ideal for coordinating complex APAC operations. It plays a central role in regional strategy and oversight.
Together, these markets create a dynamic and interconnected ecosystem. The opportunity is not simply to choose one APAC market but to develop a regional strategy that draws on the right strengths from the right locations at the right stage of development.
Conclusion: An Invitation to Global Innovation
The rise of the APAC region represents more than just a geographic expansion. It is a fundamental shift in what is possible in healthcare and global drug development. From transformative oncology assets to affordable biosimilars that redefine patient access, the work being done in APAC is changing the global landscape of medicine.
For sponsors, the message is clear: The region is no longer a frontier to be explored, but a vital partner in bringing the next generation of life-saving therapies to patients worldwide.
Organizations that continue to view the region only through the lens of cost or recruitment may miss a much larger opportunity. The future of global clinical development will increasingly depend on the ability to integrate APAC’s scale, innovation, quality and strategic diversity into global development planning from the very beginning.
Turn APAC’s advantages into global development success. Connect with our APAC Clinical Development experts.
Reference
- Australian Clinical Trials Alliance. Annual Report 2024–25. Published 2025. Accessed June 2026.
https://clinicaltrialsalliance.org.au/wp-content/uploads/2025/11/ACTA_2024_25AnnualReport_WEB.pdf
Contributor
Ken Lee
Managing Director and Region Head, Clinical Development, Asia Pacific
Related Content
Looking for exclusive insight?
